This review critically examines the growing popularity of custom-compounded bioidentical hormone therapy (CBHT) and highlights significant safety concerns, including severe adverse events from compounding errors, such as deaths from contaminated products and cases of end-stage renal failure. Oral estrogens, particularly in excessive doses, are linked to an increased risk of
